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SUMMARY
Chapter 1 gives an overview on the development and application of antiarrhythmic
drugs in general and the classification of antiarrhythmic drugs. The development of
flecainide acetate, a "fluorine-for-hydrogen substitution" derivative of procainamide,
started in7966. The most important pharmacokinetic properties are its good absorp-
tion without significant first pass effect by the liver, its metabolisation (dealkylation)
by the liver and inactivation of metabolites by glucuronidation and their excretion by
the kidneys. Plasma half-lives range from 7 to 22 hours and are prolonged in elderly
subjects with frequent ventricular premature beats, congestive heart failure and
impaired renal function. The electrophysiological investigations showed dose related
prolongation of QRS duration, HV-, AH- and PR interval. Refractory periods were less
influenced. Especially in patients with AV node dysfunction flecainide should be
carefully administered. In contrast, patients with sinus node dysfunction seem to be
influenced to a lesser degree.
The second chapter deals with the value of flecainide acetate in supraventricular
tachycardias as reported in the literature together with parts of our finding. Flecainide
acetate in a dose of 2mg/kg is highly efficacious in the termination of recent- onset
atrial fibrillation (up to 90%) , atrial tachycardias (92%) and AV reentry tachycardias
(90%). However, the efficacy in the termination of atrial flutter is poor. Efficacy during
long-term therapy of supraventricular arrhythmias with flecainide acetate is also
satisfactory.
In chapter 3 a review on the efficacy of flecainide acetate in ventricular arrhythmias is
presented. Flecainide acetate was demonstrated to be very effective in suppression of
premature ventricular beats, couplets and nonsustained ventricular tachycardias.
However, the treatment of sustained ventricular tachycardias and fibrillation is often
disappointing, although the efficacy of flecainide was not shown to be inferior to that
of amiodarone, which is generally considered to be the most effective drug in these
circumstances. Also a review of proarrhythmic effects is presented in this chapter.
In chapter 4 we describe 9 patients with congestive heart failure class III according to
theNYHA. Thepatients couldbe divided in2 groups interms of theirpharmacokinetic
and haemodynamic properties. The first group of 5 patients showed a relatively short
plasma halflife, normal plasma clearance, normal renal function, normal or slightly
enlarged left atrium and left ventricle. In contrast, the second group showed prolonged
plasma half-life, low plasma clearance, impaired renal function, enlarged left atrium
and ventricle. Although maximum plasma levels were low in the second group, the
antiarrhythmic efficacy was even better compared to the first group. We presume that
a different relation between plasma and tissue levels of flecainide acetate caused this
good antiarrhythmic efficacy. Furthermore, after an initial decrease of plasma levels a
second maximum was found about 2 to 3 hours after the infusion. We presume that
reabsorption as a consequence of enterohepatic recirculation may lead to a second rise
of plasma levels, especially in patients with impaired renal and cardiac function in
whom liver excretion and metabolisation become increasingly important.
In chapter 5 we describe the acute conversion of recent onset and chronic atrial
fibrillation with oral versus iv administered flecainide acetate. In recent onset atrial fib-
rillation both regimens had a comparable efficacy (77% and777o respectively).
The only difference between the 2 regimens was the mean time to conversion (as may
be expected), eg1.}4minutes after oral and 14 minutes after starting the iv administra-
tion of flecainide. Chronic atrial fibrillation could not be converted bv anv of these
regimens.
In chapter 6 we compare the efficacy of flecainide 100 mg b.i.d. to quinidine 500 mg
b.i.d. in 26 patients with paroxysmal atrial fibrillation. An almost maximal effect was
obtained with flecainide in a dosage of 100 mg twice daily (46% of thepatients showed
complete abolition of tachycardias). An increase of the dosage to 100 mg t.i.d. resulted
in a large number of side effects whereas efficacy was almost unchanged. On quinidine
therapy the efficacy on the first regimen of 500 mg b.i.d. was significantly lower
compared to flecainide 100 mg twice daily (777o only). A comparable efficacy could be
reached by increasing the dosage of quinidine from 500 mg b.i.d. to 750 mg b.i.d. (357o
of the patients no longer showed tachycardias).
However, the number of side effects was much higher during treatment with quini-
dine, with the same efficacy as far as prevention of paroxysms of atrial fibrillation is
concerned.
In chapter 7 we describe the efficacy of iv flecainide acetate in 2 patients with recent
onset atrial fibrillation and rapid ventricular response in the setting of a Wolff-
Parkinson-White syndrome. Both patients had a short antegrade refractory period of
the accessory pathway, the shortest RR-interval were 180 and 190 msec. Atrial fibril-
lation was terminated in both patients after slowing of the ventricular rate and regu-
larisation of the atrial activity.
In chapter 8 the efficacy of flecainide acetate in the long term treatment of supraven-
tricular tachycardias in 20 patients was described. Furthermore, the value of pro-
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cainide 6 patients no longer had inducible tachycardias. None of the patients with a
Wolff-Parkinson-White syndrome showed atrial fibrillation after flecainide. During a
mean follow-up period of 11 months, 65Vo f the patients had no recurrence. Positive
and negative predictive value of the electrophysiological investigation was 50 and
100Va, respectively. Patients with a Wolff-Parkinson-White syndrome, especially
younger patients, prefer more and more surgical intervention even when medical
treatment is successful.
In chapter 9 the results of flecainide in the treatment of sustained ventricular
tachycardia or ventricular fibrillation are presented. In 37 patients the aetiology of the
tachyarrhythmia was coronary artery disease and in 13 patients other aetiologies
(cardiomyopathy, valvular disease or idiopathic). During a 4 week in hospital period
therapy failed in 8 patients with coronary artery disease. In 6 patients recurrence of
tachycardias developed (including proarrhythmic effects) and in 2 patients side effects
necessitated iscontinuation of flecainide. Thirty-eightpatientscompleted afollow-up
period of 1 year with an overall success rate based on intention to treat of 54%. Patients
with tachyarrhythmias based on coronary artery disease had a significantly lower
ejection fraction (31% versus 47%) and earlier recurrences (7.5 weeks versus 20 weeks)
compared to the patients with tachyarrhythmias based on other aetiologies. Therefore,
calculated after 4 weeks hospitalisation patients with tachyarrhythmias based on
coronary artery disease showed a higher success rate compared to patients with
arrhythmias based on other aetiologies (78Vo versus 55%). Failures in the group with
arrhythmias based on coronary artery disease had a significantly lower ejection frac-
tion. Programmed electrical stimulation (N = 28) showed a positive and negative
predictive value of 40 %. Holter monitoring (N = 24) showed a positive and negative
predictive value of 70 and 86% respectively. Since exercise testing (N = 30) showed
arrhythmias only in 20% of the patients the number is too small for a reliable
conclusion.
In conclusion, we have established that flecainide is a valuable drug in the treatment
of almost all cardiac arrhythmias except atrial flutter. Efficacy in termination of recent
onset-atrial fibrillation, atrial tachycardias and AV-reentry tachycardias has been
proven beyond any doubt. It may even be preferred over quinidine in terms of efficacl
and toxicity, in the prevention of paroxysms of atrial fibrillation. Furthermore, we hav,
shown that flecainide is very effective in the long-term treatment of sustained ventricu
lar and supraventricular tachycardias, including atrial fibrillation in the setting of th
Wolff-Parkinson-White syndrome. However, care should be taken in starting flr
cainide or in adjustment of the dose, especially in patients with coronary artery disear
and impaired left ventricular function.
